# Dronabinol Cuts PTSD Nightmares in a New Randomized Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dronabinol-ptsd-nightmares-randomized-trial/ > **Published:** 2026-08-05T17:14:40-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:55:03-04:00 > **Clinical Summary:** Dronabinol PTSD nightmares: a randomized, placebo-controlled trial in more than 170 adults found nightly oral THC significantly reduced PTSD nightmares. --- CED Clinical Relevance #90 Clinical Evidence Update A multicenter, double-blind, placebo-controlled randomized trial in more than 170 adults with PTSD found that ten weeks of bedtime dronabinol (oral THC) reduced nightmare burden significantly more than placebo, published August 5, 2026 in Nature Medicine. The patient-relevant primary endpoint, adequate sample size, and top-tier journal place this well above the usual newsjack threshold. Clinical Insight | CED Clinic Nightmares are one of the most disabling and treatment-resistant symptoms of PTSD, and no medication has been specifically approved for them. This trial, led by Prof. Stefan Ropke’s group at Charite – Universitatsmedizin Berlin, randomized more than 170 adults with PTSD and frequent, intense nightmares to nightly oral dronabinol drops or an identical-looking, cannabis-flavored placebo for ten weeks. Nightmare burden, rated on a zero to eight point scale, fell by an average of 3.7 points in the dronabinol group compared with 2.2 points with placebo. More than a third of dronabinol patients stopped having nightmares entirely, another 21 percent cut their nightmare burden at least in half, and about five in six felt their health had meaningfully improved. Overall PTSD severity and depression scores did not change conclusively, so this looks like a targeted effect on nightmares and sleep rather than a treatment for PTSD as a whole. No severe side effects or withdrawal symptoms were reported, though dizziness, headache, and increased appetite were more common with dronabinol than placebo. PTSDNightmaresDronabinolRandomized TrialSleep Audience PTSD patients and caregivers, trauma clinicians, psychiatrists, sleep medicine specialists, and cannabis clinicians counseling patients on nightmare-focused treatment options Primary Topic A multicenter randomized, double-blind, placebo-controlled trial testing oral dronabinol for nightmares in adults with PTSD, published in Nature Medicine on August 5, 2026 Source [Read the Charite press release ](https://www.news-medical.net/news/20260805/Medical-cannabis-compound-alleviates-nightmares-associated-with-PTSD.aspx)  |   **Read the PDF** A ten-week, multicenter, double-blind, placebo-controlled trial gave more than 170 adults with PTSD nightly oral dronabinol drops or a matched placebo. Nightmare burden fell significantly more with dronabinol than placebo, more than a third of treated patients stopped having nightmares altogether, and no severe side effects or withdrawal symptoms were reported. What This Study Teaches Us This trial shows that a specific cannabinoid, dosed at bedtime, can meaningfully reduce nightmare frequency and severity in PTSD without necessarily changing overall PTSD severity or depression. That distinction, a targeted effect on one disabling symptom rather than a cure for the underlying disorder, is exactly the kind of nuance that should guide how this evidence gets used in practice. Why This Matters Nightmares drive much of the nighttime suffering in PTSD: fear of sleep, chronic sleep deprivation, and repeated re-experiencing of trauma. Existing options such as prazosin and other repurposed medications have inconsistent evidence, and no drug is specifically approved for PTSD nightmares in the United States or Germany. A randomized trial of this size, with a validated nightmare outcome measure and real safety follow-up, gives clinicians something concrete to weigh against those limited alternatives. Study Snapshot Study Type Multicenter, randomized (1:1), double-blind, placebo-controlled, parallel-group trial Population More than 170 adults with PTSD and frequent, intense nightmares Intervention Oral dronabinol drops, once daily before bedtime Comparator Identical-looking, cannabis-flavored placebo Duration 10 weeks Primary Outcome Nightmare burden on a 0 to 8 point scale Primary Result Mean decrease of 3.7 points with dronabinol versus 2.2 points with placebo Responder Detail More than one third of dronabinol patients had complete resolution of nightmares; another 21 percent had nightmare burden reduced by at least half Global Impression About five in six dronabinol patients reported meaningfully improved health PTSD and Depression Severity Did not change conclusively in either group Safety No severe side effects or withdrawal symptoms; dizziness, headache, and increased appetite more frequent with dronabinol Sites Charite – Universitatsmedizin Berlin (Benjamin Franklin Campus and St. Hedwig Hospital), University Medical Center Hamburg-Eppendorf, Central Institute for Mental Health Mannheim Journal Nature Medicine Published August 5, 2026 DOI 10.1038/s41591-026-04546-9  |  **Read the PDF** PMID Not yet indexed in PubMed as of this post Trial Registration Protocol registered as the THC PTSD-trial (ClinicalTrials.gov NCT04448808) Funding Note Study support included the pharmaceutical company Bionorica SE, a manufacturer of cannabinoid medicines, which is a disclosure worth weighing when reading the results Clinical Bottom Line In a well-powered randomized trial, ten weeks of nightly oral dronabinol reduced PTSD-related nightmares significantly more than placebo, with a substantial share of patients becoming nightmare-free, but the drug did not clearly change overall PTSD severity or depression, and industry funding from a cannabinoid manufacturer is a relevant disclosure. What the Trial Tested Researchers at Charite – Universitatsmedizin Berlin, together with colleagues in Hamburg and Mannheim, randomized more than 170 adults with PTSD and frequent, intense nightmares to nightly oral dronabinol drops or a matched, cannabis-flavored placebo for ten weeks. Neither participants nor treating clinicians knew who was receiving active drug, the standard double-blind design that limits expectation effects on a symptom, nightmares, that is otherwise hard to measure objectively. Nightmares Improved More With Dronabinol Nightmare burden, scored on a zero to eight point scale, fell by an average of 3.7 points in the dronabinol group compared with 2.2 points in the placebo group, a difference the study authors describe as clearly noticeable to patients. More than a third of dronabinol patients reported no nightmares at all after ten weeks, another 21 percent had their nightmare burden cut at least in half, and roughly five out of six felt their health had meaningfully improved. The Effect Looks Targeted, Not Global Overall PTSD severity and depression scores did not change conclusively in either group, which means this trial supports a specific effect on nightmares and sleep rather than a broad improvement across all PTSD symptoms. That distinction matters clinically. A medication that interrupts nightmares without resolving hypervigilance, avoidance, or intrusive daytime memories is still valuable, but it should be counseled as symptom-targeted care, not as [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) on its own. Safety Signal Looks Reassuring So Far No severe side effects were reported, and the study team observed no withdrawal symptoms after participants stopped their evening doses at the end of the ten-week period. Dizziness, headache, and increased appetite were reported more often in the dronabinol group than with placebo, all classified as mild to moderate. Longer-term safety and tolerance over months or years of use were not addressed by this trial. What to Weigh Before Overinterpreting The trial used a specific pharmaceutical formulation, oral dronabinol drops dosed nightly, not inhaled or whole-plant cannabis and not the wide range of products and ratios patients encounter in real-world [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use. Study support included Bionorica SE, a pharmaceutical company that manufactures cannabinoid medicines. Industry funding does not invalidate a well-designed, double-blind, placebo-controlled trial, but it belongs in any honest summary of the evidence, alongside the open question of whether benefits persist or tolerance develops beyond ten weeks. How Strong Is This Evidence? This is a randomized, double-blind, placebo-controlled, multicenter trial in the population of direct clinical interest, adults with PTSD and frequent nightmares, with an adequate sample size of more than 170 participants and a validated nightmare burden outcome. That combination of design, population match, and sample size places it well above single-center pilots, open-label studies, or retrospective surveys, and above the usual bar for a full clinical evidence update. Where This Paper Deserves Skepticism A careful reader should note that the primary benefit was specific to nightmares, while overall PTSD severity and depression did not change conclusively, so the trial should not be read as evidence that dronabinol treats PTSD broadly. Industry funding from a cannabinoid manufacturer, Bionorica SE, is a disclosure that warrants transparency, even though it does not by itself undermine a double-blind, placebo-controlled design. The ten-week duration also leaves open whether benefits are durable or whether tolerance develops with continued nightly dosing, a question the researchers themselves flag as their next step. What This Paper Does Not Show This trial does not show that dronabinol treats PTSD as a whole, that it improves daytime PTSD symptoms such as avoidance or hypervigilance, that benefits persist beyond ten weeks, that tolerance will not develop with longer use, or that inhaled or whole-plant cannabis products would produce similar effects. It also does not establish long-term safety beyond the trial window. How This Fits With the Broader Clinical Conversation PTSD nightmares have historically been treated by repurposing medications such as prazosin, with inconsistent trial results and no cannabinoid-specific option approved anywhere. This trial is among the largest randomized tests of a cannabinoid for this specific, disabling symptom to date. The finding fits a broader pattern in cannabinoid sleep research: THC’s known effect on reducing REM sleep intensity offers a plausible mechanism for blunting nightmare content, which the study authors explicitly invoke. The next useful step would be longer follow-up, comparison against existing nightmare-focused treatments such as prazosin, and replication independent of industry funding. Dr. Caplan’s Take *A well-powered, double-blind trial showing a specific, meaningful reduction in PTSD nightmares is a genuinely useful addition to a field with very few validated options for this symptom. The size of the effect, more than a third of patients becoming nightmare-free, is clinically significant, not marginal.* *What keeps me measured is the same thing that should keep any clinician measured: this is a symptom-targeted result, not a PTSD cure, it used a specific pharmaceutical formulation rather than the products most patients actually access, and industry funding needs to be named plainly rather than buried. I would treat this as real evidence for nightmare-focused dronabinol trials in appropriate patients, monitored closely, not as a green light for open-ended cannabis use in PTSD.* What a Careful Reader Should Take Away Ten weeks of nightly oral dronabinol reduced PTSD nightmares significantly more than placebo in a well-designed randomized trial, with a meaningful share of patients becoming nightmare-free and no severe safety signal, but the benefit looked specific to nightmares rather than PTSD overall, and durability, tolerance, and industry funding all deserve continued scrutiny. Evidence Interpretation Guide ## How to Read a Positive Nightmare Trial Without Overselling It A large, randomized, placebo-controlled trial with a clear positive result is exactly the kind of study that gets flattened into an oversimplified headline. Four checks keep this trial’s real contribution in view without overstating what it proves. ### A Four-Step Reading Frame **Confirm what improved**Nightmare burden improved significantly. Overall PTSD severity and depression did not change conclusively. **Note the formulation**This was pharmaceutical oral dronabinol dosed nightly, not inhaled or whole-plant cannabis products. **Weigh the funding disclosure**A cannabinoid manufacturer, Bionorica SE, supported the study, which belongs in any fair summary. **Watch the open questions**Ten weeks does not establish durability or rule out tolerance with longer use. The Research Question Does ten weeks of nightly oral dronabinol reduce nightmare burden in adults with PTSD compared with placebo, and is it safe to use? The Patient Question Could a monitored trial of dronabinol help stop my nightmares, even if it does not resolve every symptom of my PTSD? The Bottom Line The trial suggests it might help nightmares specifically, with a favorable early safety profile, while PTSD overall and long-term durability remain open questions. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives keep a genuinely positive, well-designed trial from being oversold as a cure for PTSD or dismissed because of its industry funding. #### A Real Option for a Symptom That Is Often Ignored If nightmares are the most disruptive part of your PTSD, this trial offers real, randomized evidence that a specific cannabinoid medication can reduce them, with a meaningful share of patients becoming nightmare-free. It is not evidence that dronabinol resolves PTSD overall, so pair any conversation about this option with your broader trauma treatment plan rather than in place of it. Lens takeaway Ask specifically about nightmare-focused treatment, not a general PTSD cure. #### A Targeted Tool, Not a Blanket Prescription The trial supports considering dronabinol specifically for nightmare burden in PTSD patients who have not responded to existing options such as prazosin, with structured monitoring for the mild-to-moderate side effects observed. Document target symptoms, baseline nightmare frequency, and a review date, since durability beyond ten weeks was not tested. Lens takeaway Prescribe to the symptom studied, and monitor rather than assume durability. #### Positive Trials From Industry-Funded Work Still Need Scrutiny A double-blind, placebo-controlled design is a real methodological strength, but the involvement of a cannabinoid manufacturer as study support is a disclosure that deserves to be stated plainly, not minimized. The lack of conclusive change in overall PTSD severity or depression should temper any headline suggesting dronabinol treats PTSD broadly. Lens takeaway Strong design and industry funding can both be true at once; report both. #### A Plausible Mechanism Worth Tracking The proposed mechanism, THC’s known effect of reducing REM sleep intensity, offers a biologically coherent explanation for why nightmare content specifically would improve. Sleep specialists should watch for replication that separates effects on nightmare content from broader sleep architecture changes, which this trial did not report in detail. Lens takeaway A credible mechanism supports the finding but is not proof of it. #### Relevant to a Population With Few Good Options PTSD nightmares are especially common and disabling among combat veterans and other trauma survivors who have often tried and failed multiple medications for this specific symptom. A validated, symptom-specific option is meaningful for this population, though access, cost, and formulation differences from what is currently available will shape how directly this trial translates into practice. Lens takeaway A validated nightmare-specific option matters for a population underserved by existing drugs. #### Ten Weeks Is a Start, Not an Answer A ten-week trial cannot tell us whether the benefit holds up over months or years of continued use, or whether tolerance develops, both of which the researchers explicitly flag as next steps. The trial also does not report how nightmare improvement was distributed across trauma types, prior treatment history, or baseline severity, details that would help identify who is most likely to benefit. Lens takeaway Durability and responder characteristics remain open questions. #### A Step Toward an Approved Nightmare Treatment No medication is currently approved specifically for PTSD nightmares in the United States or Germany, so a positive, adequately powered randomized trial is a meaningful step toward regulatory consideration. Policymakers and formulary committees should still wait for replication and longer-term data before treating this as a settled approval pathway. Lens takeaway One strong trial supports further regulatory review, not immediate policy change. #### Precise Framing Prevents Overreach Headlines describing this as a cure for PTSD would misrepresent a trial that specifically improved nightmares without conclusively changing overall PTSD severity. Communicating the actual, narrower finding protects patient expectations and keeps trust in [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) intact as more trials follow. Lens takeaway Report the nightmare-specific finding accurately rather than generalizing it. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Dronabinol+Cuts+PTSD+Nightmares+in+a+New+Randomized+Trial&url=https%3A%2F%2Fcedclinic.com%2Fdronabinol-ptsd-nightmares-randomized-trial%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdronabinol-ptsd-nightmares-randomized-trial%2F) [BlueSky](https://bsky.app/intent/compose?text=Dronabinol+Cuts+PTSD+Nightmares+in+a+New+Randomized+Trial%20https%3A%2F%2Fcedclinic.com%2Fdronabinol-ptsd-nightmares-randomized-trial%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Ropke S, et al. Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial. Nature Medicine. 2026 Aug 5. DOI: 10.1038/s41591-026-04546-9.](https://www.news-medical.net/news/20260805/Medical-cannabis-compound-alleviates-nightmares-associated-with-PTSD.aspx) Related Reading at CED Clinic Continue exploring the evidence [THC and PTSD: What a New Brain-Imaging Trial on Emotion Regulation Actually Found](https://cedclinic.com/thc-dose-finding-clinical-trial-standardized-ptsd-reappraisal/) A CED review of a separate dronabinol trial in PTSD, this one testing brain activity during cognitive reappraisal rather than nightmares, useful context for how THC is being studied across PTSD mechanisms. [Read the cognitive reappraisal trial context](https://cedclinic.com/thc-dose-finding-clinical-trial-standardized-ptsd-reappraisal/) [Dronabinol for Chronic Low Back Pain: What the Veterans Trial Will Actually Test](https://cedclinic.com/dronabinol-chronic-low-back-pain/) Another CED look at dronabinol under study in a veteran-relevant population, useful for comparing how this synthetic THC product is being tested across conditions. [Read the veterans trial context](https://cedclinic.com/dronabinol-chronic-low-back-pain/) CED Cannabis Science Digest: 3 CUD, Fibromyalgia, and PTSD Signals Worth Watching CED’s earlier roundup flagged emerging PTSD-relevant cannabis science signals; this randomized trial is a direct, higher-quality follow-through on that watchlist. Read the earlier PTSD signal roundup Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [A promising cure for PTSD: Cannabis-based medicine suppresses aversive memory and eases anxiety](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/) [Cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/) PTSD treatments show promise in suppressing aversive memories and easing anxiety symptoms. Research indicates low doses can alleviate anxiety and facilitate fear memory extinction. This approach… Covers a closely related topic; this CED post is older by about 1884 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/) ## Frequently Asked Questions What did this trial test? A multicenter, randomized, double-blind, placebo-controlled trial gave more than 170 adults with PTSD and frequent nightmares either nightly oral dronabinol drops or an identical-looking placebo for ten weeks, measuring nightmare burden on a zero to eight point scale. What is dronabinol? Dronabinol is a pharmaceutical oral form of THC, the principal psychoactive compound in the cannabis plant, available by prescription and already used in other conditions such as pain and [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/). How much did nightmares improve? Nightmare burden fell by an average of 3.7 points on the 0 to 8 scale with dronabinol, compared with 2.2 points with placebo. More than a third of dronabinol patients had no nightmares at all after ten weeks. Did the trial improve PTSD overall, not just nightmares? No. Overall PTSD severity and depression scores did not change conclusively in either group, so the benefit looks specific to nightmares and sleep rather than PTSD as a whole. Was dronabinol safe in this trial? No severe side effects or withdrawal symptoms were reported. Dizziness, headache, and increased appetite were more common in the dronabinol group than with placebo, all described as mild to moderate. Is this the same as smoking or vaping cannabis for PTSD? No. The trial used a specific pharmaceutical formulation, oral dronabinol drops taken nightly, not inhaled or whole-plant cannabis products, so the results should not be assumed to apply to other cannabis forms or doses. Who funded or supported this study? The research was led by Charite – Universitatsmedizin Berlin with partner sites in Hamburg and Mannheim, and study support included the pharmaceutical company Bionorica SE, which manufactures cannabinoid medicines, a disclosure worth weighing when reading the results. How long were patients followed? Patients were treated and assessed over a ten-week period. The researchers have said they next want to study whether benefits and safety hold up over longer-term use or whether tolerance develops. Is dronabinol approved specifically for PTSD nightmares? No. As of this trial, no medication is approved specifically for PTSD-related nightmares in the United States or Germany. This trial is evidence toward that possibility, not an approval. What should someone with PTSD nightmares do with this information? Discuss it with a treating clinician as one option among existing nightmare-focused approaches, understanding that this trial supports a targeted, monitored trial of dronabinol for nightmares specifically, not a general cannabis recommendation for PTSD.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).